Episode Details

Drs. Montesi and Martinez discuss how the emerging PRIME-PPF clinical cohort study and biomarker research will sharpen definitions of disease progression and transform treatment decisions in non-IPF ILD. They highlight the potential for clinicians to use integrated data (eg, symptoms, physiology, imaging, and circulating proteomic signatures) to initiate antifibrotic and combination therapies earlier, tailoring them to individual patients while also balancing side effects and standard immunomodulatory care.